We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
(Approval lapsed) NELARABINE-REACH 5mg/mL solution for infusion
Section 19A approved medicine
(Approval lapsed) NELARABINE-REACH 5mg/mL solution for infusion
Section 19A approval holder
Reach Pharmaceuticals Pty Ltd ABN 25 623 897 183
Phone
0422 429 648
Approved until
Status
Expired
Indication(s)
NELARABINE-REACH nelarabine 5mg/mL solution for infusion is indicated for the treatment of patients with relapsing/ refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
Images
